|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2004-6-9
|
|
pubmed:abstractText |
In MAG-camptothecin (MAG-CPT), the topoisomerase inhibitor camptothecin is linked to a water-soluble polymer. Preclinical experiments showed enhanced antitumour efficacy and limited toxicity compared to camptothecin alone. Prior phase I trials guided the regimen used in this study. The objectives were to determine the maximum tolerated dose, dose-limiting toxicities, safety profile, and pharmacokinetics of weekly MAG-CPT. Patients with solid tumours received MAG-CPT intravenously administered weekly for 3 weeks in 4-week cycles. At the starting dose level (80 mg x m(-2) week(-1)), no dose-limiting toxicities occurred during the first cycle (n=3). Subsequently, three patients were enrolled at the second dose level (120 mg x m(-2) week(-1)). Two of three patients at the 80 mg x m(-2) week(-1) cohort developed haemorrhagic cystitis (grade 1/3 dysuria and grade 2/3 haematuria) during the second and third cycles. Next, the 80 mg x m(-2) week(-1) cohort was enlarged to a total of six patients. One other patient at this dose level experienced grade 1 haematuria. At 120 mg x m(-2) week(-1), grade 1 bladder toxicity occurred in two of three patients. Dose escalation was stopped at 120 mg x m(-2) week(-1). Cumulative bladder toxicity was dose-limiting toxicity at 80 mg x m(-2) week(-1). Pharmacokinetics revealed highly variable urinary camptothecin excretion, associated with bladder toxicity. Due to cumulative bladder toxicity, weekly MAG-CPT is not a suitable regimen for treatment of patients with solid tumours.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/15150611-10655437,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15150611-10699275,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15150611-10699287,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15150611-10766368,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15150611-11335787,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15150611-11896118,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15150611-12135091,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15150611-12237769,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15150611-1244564,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15150611-12904897,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15150611-1560438,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15150611-1846923,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15150611-1995300,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15150611-2548584,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15150611-2692843,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15150611-4946015,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15150611-5081595,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15150611-8853931,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15150611-8995509,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15150611-9829738,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15150611-9918196,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15150611-9918206
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0007-0920
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
14
|
|
pubmed:volume |
90
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2261-7
|
|
pubmed:dateRevised |
2010-9-20
|
|
pubmed:meshHeading |
pubmed-meshheading:15150611-Adult,
pubmed-meshheading:15150611-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:15150611-Camptothecin,
pubmed-meshheading:15150611-Cystitis,
pubmed-meshheading:15150611-Drug Administration Schedule,
pubmed-meshheading:15150611-Drug Delivery Systems,
pubmed-meshheading:15150611-Female,
pubmed-meshheading:15150611-Humans,
pubmed-meshheading:15150611-Infusions, Intravenous,
pubmed-meshheading:15150611-Male,
pubmed-meshheading:15150611-Maximum Tolerated Dose,
pubmed-meshheading:15150611-Middle Aged,
pubmed-meshheading:15150611-Neoplasms,
pubmed-meshheading:15150611-Polyvinyls
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours.
|
|
pubmed:affiliation |
Department of Pulmonary Diseases, University Hospital Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase I
|
